Oct. 7, 2009 (Business Wire) -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has been named to the top spot in the MassEcon Sixth Annual Team Massachusetts Economic Impact Awards in the Greater Boston Region. Two other pharmaceutical companies earning honors in the silver and bronze levels led to a sweep by life science companies in the Greater Boston Region.
The Massachusetts Alliance for Economic Development (MassEcon) is a private, non-profit partnership of business, industry leaders, and government dedicated to the economic growth of Massachusetts. Companies were judged on investment in facilities, job growth, and community involvement. In 2008 Cubist added 35,000 square feet of laboratory space at its 65 Hayden Avenue facility in Lexington. The company has a request before the Town of Lexington to add another 110,000 square feet of Laboratory space over the next two years. Cubist currently employs 579 people, about 350 of them in Lexington, reflecting a 28 percent increase since January 2008.
Cubist President and CEO Michael Bonney said, “Cubist recognizes the unique blend of resources that Massachusetts presents to employers in the life science sector: supportive and collaborative state and local government, world-class schools of higher learning and a commitment to early learning, and an unmatched talent pool. I cannot imagine a better place to start and grow a life science business.”
Susan Houston, Executive Director of MassEcon, said “Each year we are proud to confer these awards on companies that invest in Massachusetts. Cubist distinguished itself in so many areas and exemplifies what is best about Massachusetts companies.”
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM® I.V. (meropenem for injection) in the U.S. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials — CONSERV™-1 and CONSERV™-2 — for the reduction of blood loss during cardiac surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam’s RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist’s web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.
AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.
